Research identifies a culprit behind cancer immunotherapy failures
A joint UK-Finland academic project has provided new evidence about a longstanding cancer treatment issue: why does immunotherapy fail for many patients?
Senior author of the study, the University of Turku's Dr. Maija Hollmén said the research shed light on how cancer hides from the body’s immune system.
“This research gives us a new, clearer picture of how cancer hides from the body’s immune system. We’ve discovered a key signal that cancer uses to turn the immune system off, which confirms that our drug is aiming at the right target,” she stated.
Scientists had already identified the presence of a protein called Clever-1 as a receptor present on immune cells that can suppress responses to cancer.
Now the Turku researchers, working with colleagues at University of Birmingham, have employed sophisticated new techniques to identify a secreted form of the Clever-1 protein called sClever-1.
This form systematically suppresses the T cells vital to combatting cancer, say the researchers in their study published in Theranostics.
They say their work could now help to identify which patients’ bodies are likely to reject certain immunotherapy treatments.
Furthermore, the research also established that employing the investigational anti-Clever-1 antibody, bexmarilimab directly inhibited the secretion of sClever-1.
Co-author of the study professor, Shishir Shetty of the University of Birmingham and the NIHR Birmingham Biomedical Research Centre, explained the implications.
“As we still see many patients with solid organ cancers where immunotherapy is ineffective… the link we have found is very important. It seems that high levels of sClever-1 in the blood can predict if a patient’s cancer will resist standard immunotherapy,” he said.
"This could allow us to identify patients who might not respond to a certain treatment. For such patients, beximarilimab can be used to make immunotherapy effective again. Ultimately, understanding this helps us create smarter combination treatments for people with advanced cancers.”
Pic: National Cancer Institute
Related Content
When plasma leaves the laboratory
The orbital laboratory is evolving into something more ambitious, a controlled industrial environment for producing next-generation materials, explains Ed Smith and Andrew Griffiths. …
London Lab Live: A capital investment
Launched last year as part of the Future Labs’ stable, the London show looks here to stay. One year on, …
Lab gloves could inflate microplastics readings suggests study
Scientists may be overestimating their assessments of microplastics pollution, with the cause lying literally in their own hands, suggests a …
